Search research articles
Contact Us
Filters
Showing results (181-190 of 269) with videos related to
Page
of 27
Sort By:
Gastroenterology
|
September 2, 2021
PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis
William J Sandborn, Larry C Mattheakis, Nishit B Modi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 7, 2026
Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn's disease: Results from the VIVID-2 Open-Label Extension Trial
Bruce E Sands, Edward L Barnes, Geert D'Haens, et al.
The Lancet. Gastroenterology & Hepatology
|
November 19, 2021
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
Silvio Danese, Jean-Frederic Colombel, Milan Lukas, et al.
Journal of Crohn'S & Colitis
|
February 27, 2023
Mercaptopurine for the Treatment of Ulcerative Colitis: A Randomized Placebo-Controlled Trial
Mark Löwenberg, Adriaan Volkers, Sara van Gennep, et al.
The Lancet. Gastroenterology & Hepatology
|
January 10, 2025
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial
Bruce E Sands, Remo Panaccione, Geert D'Haens, et al.
The Lancet. Gastroenterology & Hepatology
|
February 5, 2022
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
Silvio Danese, Severine Vermeire, Geert D'Haens, et al.
Alimentary Pharmacology & Therapeutics
|
November 30, 2023
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST
Laurent Peyrin-Biroulet, Séverine Vermeire, Geert D'Haens, et al.
Journal of Crohn'S & Colitis
|
September 22, 2023
Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label Study
Geert D'Haens, Michael Eberhardson, Zeljko Cabrijan, et al.
The New England Journal of Medicine
|
September 29, 2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
William J Sandborn, Brian G Feagan, Geert D'Haens, et al.
The American Journal of Gastroenterology
|
May 9, 2020
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors
Parambir S Dulai, Robert Battat, Maria Barsky, et al.
Page
of 27
Search research articles
Search
Showing results (181-190 of 269) with videos related to
Sort By:
Page
of 27
Gastroenterology
|
September 2, 2021
PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis
William J Sandborn, Larry C Mattheakis, Nishit B Modi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 7, 2026
Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn's disease: Results from the VIVID-2 Open-Label Extension Trial
Bruce E Sands, Edward L Barnes, Geert D'Haens, et al.
The Lancet. Gastroenterology & Hepatology
|
November 19, 2021
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
Silvio Danese, Jean-Frederic Colombel, Milan Lukas, et al.
Journal of Crohn'S & Colitis
|
February 27, 2023
Mercaptopurine for the Treatment of Ulcerative Colitis: A Randomized Placebo-Controlled Trial
Mark Löwenberg, Adriaan Volkers, Sara van Gennep, et al.
The Lancet. Gastroenterology & Hepatology
|
January 10, 2025
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial
Bruce E Sands, Remo Panaccione, Geert D'Haens, et al.
The Lancet. Gastroenterology & Hepatology
|
February 5, 2022
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
Silvio Danese, Severine Vermeire, Geert D'Haens, et al.
Alimentary Pharmacology & Therapeutics
|
November 30, 2023
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST
Laurent Peyrin-Biroulet, Séverine Vermeire, Geert D'Haens, et al.
Journal of Crohn'S & Colitis
|
September 22, 2023
Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label Study
Geert D'Haens, Michael Eberhardson, Zeljko Cabrijan, et al.
The New England Journal of Medicine
|
September 29, 2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
William J Sandborn, Brian G Feagan, Geert D'Haens, et al.
The American Journal of Gastroenterology
|
May 9, 2020
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors
Parambir S Dulai, Robert Battat, Maria Barsky, et al.
Page
of 27